First Liver transplant with STEEN Solution™ performed
The first clinical liver transplant with a liver perfused with STEEN Solution™ was performed in Toronto, Canada. In total three successful liver transplants have been performed as part of a phase 1 clinical trial at Toronto General Hospital (TGH)/University Health Network.
In total three successful liver transplants were performed during the summer in Toronto, Canada. The liver was perfused with STEEN Solution™ under normothermic conditions. STEEN Solution™ was originally developed for warm perfusion and evaluation of lungs and is modified when perfusing a liver. The modified STEEN Solution™ decreases inflammation and protects the liver from injury.
“This technique will change the landscape of organ donation by improving organ preservation, allowing us to assess or ‘test drive’ the liver on the device before we transplant it into a patient. We will know how healthy that organ is before the transplant operation,” says Dr. Markus Selzner, a transplant surgeon in the Multi-Organ Transplant Program at TGH, co-investigator of the clinical trial and the transplant surgeon who performed the donor operation. After the Phase 1 safety trial they will move into subsequent phases examining efficacy.
XVIVO Perfusion’s product STEEN Solution™ (together with the XPS™) is the only FDA approved device for evaluating an organ and is currently approved in the USA for evaluation of marginal lungs prior to lung transplantation.
“With STEEN Solution™ having a proven clinical use in lungs, XVIVO perfusion is determined to investigate the clinical use of STEEN Solution™ in other organs as well as other areas of use such as cancer treatment. It is encouraging that the STEEN Solution™ liver study has started,” says Magnus Nilsson, CEO XVIVO Perfusion.
August 6, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on August 6, 2015 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: